The protocol for identification of mutations in cases of CF in developing countries would have to include a different set of mutations than those reported from western countries.
No takes yet. Share an insight, caveat, or question.
Sachdeva et al. (2012) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: